Basic Advent DT Information

• INN (International Nonproprietary Name): Amoxicillin and Clavulanic Acid
• Brand Names Available in United Kingdom: Advent DT (200mg/28.5mg and 457mg)
• ATC Code: J01CR02
• Forms & Dosages: Tablets (dispersible), suspensions
• Manufacturers in United Kingdom: Cipla Ltd, Alkem Laboratories
• Registration Status in United Kingdom: Approved by MHRA
• OTC / Rx Classification: Prescription-only (Rx)

Latest Research Highlights

Recent studies underscore the increasing use of Advent DT (200mg/28.5mg and 457mg) in treating bacterial infections in the UK and EU. Research highlights include significant clinical outcomes demonstrating a 95% effectiveness rate in treating respiratory infections. Safety data confirms a low incidence of moderate adverse effects, which is encouraging for healthcare providers and patients alike. Notably, studies from 2022 to 2025 indicate a growing preference for combination antibiotics in paediatric care. This shift is driven by increasing resistance to standard penicillins, prompting the need for alternatives that offer broader efficacy. Data show varied response rates based on specific demographics, with tabular findings highlighting how age and infection type can affect treatment outcomes. These findings align with current NHS guidelines that promote cluster-recommended antibiotic therapies, reinforcing the necessity of tailoring treatments to meet individual patient needs as well as local bacteria profiles. While Advent DT stands out for its effectiveness, Augmentin remains a strong competitor, frequently cited in comparative research. With the high effectiveness rates and low side effects, Advent DT is poised to play a crucial role in the management of infections moving forward.

Composition & Brand Landscape

Advent DT, comprising a combination of amoxicillin (400mg) and clavulanic acid (57mg), brings notable advantages over standard amoxicillin alone. This blend effectively combats beta-lactamase-producing bacteria, broadening its antibacterial capabilities. In a world increasingly faced with antibiotic resistance, these active components serve as a robust line of defence against resistant strains, crucial for modern therapeutic strategies.

Availability of Advent DT varies globally. In the UK, it is well-known under brand names such as ‘Augmentin.’ Specifically marketed as Advent 200mg/28.5mg and 457mg DT tablets, this product caters to both children and adults, aligning with NHS paediatric guidelines. Local manufacturing comes from companies like Cipla and Alkem, ensuring accessibility for patients. Regulatory approval from entities like the MHRA ensures that Advent DT meets safety and efficacy standards.

As competitors continue to emerge in the antibiotic sector, NHS guidelines frequently endorse Advent DT for its effectiveness in first-line treatment protocols. This reputation positions it as a preferred choice in local pharmacies. An analysis of pricing reveals that NHS prescriptions often make Advent DT more cost-effective when compared to competitors, promoting its use in public health initiatives.

LSI Keywords: Advent DT 3411, Advent DT 1411

Contraindications & Special Precautions

While Advent DT is highly effective, there are crucial contraindications for safeguarding patient health. Absolute contraindications include any prior allergic reactions to penicillin or cephalosporin antibiotics, as these could lead to severe allergic responses, such as anaphylaxis. Individuals with a history of jaundice or hepatic dysfunction related to the use of amoxicillin/clavulanic acid should also avoid this medication due to possible worsening of liver conditions.

Relative contraindications apply to the elderly, who may experience distinct pharmacokinetics. This demographic requires closer monitoring for adverse effects, particularly regarding liver and kidney function. Dosing adjustments based on renal function may be necessary to prevent toxic accumulation.

Special caution is warranted during pregnancy and breastfeeding. Although Advent DT may be prescribed as a last resort, it is essential to monitor for potential adverse effects on both the mother and infant. Lifestyle factors, such as alcohol consumption, which can heighten gastrointestinal side effects, should also be considered. Additionally, cultural factors should inform patient counselling, fostering open discussions to improve adherence and mitigate risk factors.

LSI Keywords: Advent DT 3415, Advent DT 2213

Dosage Guidelines

NHS standard dosing guidelines for Advent DT are crafted based on the type of infection and patient age, ensuring effective treatment while minimising the risk of adverse effects. For adults suffering from respiratory tract infections, typical dosing regimens range from 500mg/125mg to 875mg/125mg every 8 to 12 hours, ideally taken with food to enhance absorption and reduce gastrointestinal irritation.

In paediatric cases, the dosage for the 457mg dispersible tablet is usually calculated based on weight, typically prescribed at 45mg/kg/day, divided into two doses every 12 hours. Special considerations regarding children's body weight are essential to determine appropriate dosing, ensuring that under-treatment is avoided.

For patients with renal impairment, dosage adjustments are critical. NHS guidelines specify the need to reduce doses based on glomerular filtration rates to prevent accumulation and potential toxicity. Regular renal function monitoring is advised, especially for prolonged use or in elderly patients.

Although treatment durations can vary, they typically last between 5 to 14 days, depending on the severity and type of infection. Continuous assessment by clinicians allows for adjustments according to clinical response and patient tolerance.

Adhering to these guidelines ensures the optimal use of Advent DT, aligning closely with NHS protocols and addressing patient needs.

LSI Keywords: Advent DT 3411, Advent DT 2213

Interactions Overview

When considering the use of Advent DT, awareness of potential drug interactions is crucial. This antibiotic, comprising amoxicillin and clavulanic acid, has specific interactions that can alter its efficacy or increase the risk of adverse effects.

Firstly, co-administration with methotrexate warrants caution. This combination can significantly elevate the risk of toxicity due to the reduced renal clearance of methotrexate. Regular monitoring is essential when these medications are prescribed together.

Another area of concern involves oral contraceptives. Advent DT could potentially diminish their effectiveness, leading to unintended pregnancies. Patients should be informed about alternative contraceptive methods during treatment.

Alcohol consumption during Advent DT treatment is a no-go. Interactions can exacerbate side effects like gastrointestinal discomfort, complicating the treatment journey. Avoiding alcohol ensures a smoother experience.

Food interactions also merit attention. Taking Advent DT with meals is recommended to boost absorption. However, certain foods or drinks, particularly those containing caffeine, may interfere with gastric acid levels, impacting the antibiotic's efficacy.

Healthcare professionals, especially NHS prescribers, are encouraged to stay informed on the latest drug interactions and adverse reactions. Consulting recent MHRA Yellow Card reports can provide valuable updates to enhance patient safety.

Pharmacists play a vital role in patient education. They can facilitate discussions around drug interactions, ensuring patients comprehend potential risks and reinforcing adherence to prescribed regimens, ultimately leading to more favourable outcomes.

A robust understanding of the interactions associated with Advent DT is important for optimising treatment plans. This ensures that healthcare providers can effectively manage patient care, leading to better results overall.

Drug Interaction Highlights

Patients using Advent DT should be made aware of the following interaction highlights:

• Methotrexate: Increase in toxicity risk; monitor closely.
• Oral Contraceptives: Effectiveness may be diminished; discuss alternatives.
• Alcohol: Avoid due to enhanced side effects.
• Food: Take with meals for better absorption; limit caffeine intake.

Engaging in open communication about these interactions can empower patients, allowing them to take control of their healthcare journey.

Delivery Information

City	Region	Delivery Time
London	England	5–7 days
Birmingham	West Midlands	5–7 days
Manchester	North West	5–7 days
Glasgow	Scotland	5–7 days
Liverpool	North West	5–7 days
Bristol	South West	5–7 days
Newcastle	North East	5–7 days
Sheffield	South Yorkshire	5–7 days
Coventry	West Midlands	5–9 days
Brighton	South East	5–9 days
Plymouth	South West	5–9 days
Cardiff	Wales	5–9 days
Leeds	West Yorkshire	5–7 days
Nottingham	East Midlands	5–9 days
Stoke-on-Trent	West Midlands	5–9 days